Sermorelin’s original approvals

There was a real clinical job before the adult wellness reputation: testing the pituitary and treating growth hormone deficiency in children.

Diagnostic testing

The first use was an unusually direct question to a gland. Sermorelin supplies a synthetic fragment of the hypothalamic signal that prompts the anterior pituitary to release growth hormone. In the diagnostic literature summarized by Prakash and Goa, the resulting hormone response helped evaluate children suspected of growth hormone deficiency. This use received an FDA approval in 1990.

The mechanism explains the test’s appeal. Sermorelin works at the GHRH receptor on the pituitary’s growth hormone-producing cells, while the body’s feedback regulation remains involved. The history of growth hormone secretagogues describes how this differs from supplying growth hormone directly. I understand the diagnostic appeal of asking the gland to respond.

An unlabelled plaster head section with the pituitary visible beneath the brain — An illustrative teaching model showing the pituitary beneath the brain. The original diagnostic question concerned this gland’s capacity to release growth hormone.

Childhood growth

The later treatment indication was idiopathic growth hormone deficiency in prepubertal children. In the 1996 multicenter trial, first-year height velocity increased from about 4.1 cm/year to roughly 7–8 cm/year, without excessive IGF-1 generation. The outcome was growth measured over time, a much more concrete endpoint than an immediate rise in a blood test.

The 1999 review describes sustained height-velocity increases over twelve months, with preliminary findings extending to thirty-six months. It also reports a smaller growth response than with the daily somatropin comparator. The comparator earns my attention here: the review describes a treatment with a clinical effect and a comparison, rather than an unqualified success story.

FDA approved the pediatric treatment in 1997. The population matters. Those were children with a diagnosed deficiency; adult fat loss, sleep and longevity require their own clinical questions. The study-dose record sets out the historical regimens in their original contexts.

Withdrawal and FDA’s later determination

The sponsor discontinued the products in 2008 for commercial reasons. Withdrawal of marketing approval became effective June 18, 2009. In March 2013, FDA formally determined that safety and effectiveness had not caused the withdrawal. That sequence separates the commercial exit from the later legal finding about it.

The finding preserves the abbreviated application pathway for the specified strengths. It leaves the present situation intact: there is no FDA-approved finished sermorelin product currently marketed in the United States. Patient-specific preparations must meet the conditions governing Section 503A compounding; the resulting compounded medicines have no FDA approval.

I initially overinterpreted the product’s disappearance. The notice settles the reason-for-withdrawal question. It provides no adult anti-aging trial results, and a future application pathway still requires an application and an agency decision.

A chronology separating treatment approval, the sponsor’s exit and FDA’s later withdrawal finding — Three events often compressed into one story. Between the sponsor’s exit and the later FDA determination, marketing approval was withdrawn effective June 18, 2009.

Research after the original indication

The next generation of questions reaches well beyond childhood growth. The GHRH-analog development review surveys modified agonists and antagonists in metabolic, cardiac and other research. In preclinical cardiac work, related GHRH receptor agonists were studied in animal models after myocardial infarction. Those are animal findings involving other analogs.

The class is scientifically interesting because a receptor can be studied in different tissues and with different molecules. Its breadth makes precise attribution more valuable. I’d welcome a stronger adult clinical record for sermorelin itself; a growing catalogue of related compounds leaves that particular task unfinished. The adult effects page discusses the human results most often brought into this conversation.